Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Participants include Novartis Venture Fund and H&Q Life Sciences Investors.